UC Berkeley & UC San Francisco launch gene-editing initiative.

The Innovative Genomics Initiative (IGI) is a partnership between UC Berkeley and UC San Francisco researchers with the biopharmaceutical industry. The initiative aims to develop and apply gene-editing techniques for drug development.

AstraZeneca were represented at the launch following the announcement of their partnership with the IGI last week. “The science is cool, but the kind of collaborative structure we have is cool as well,” said Lorenz Mayr, vice president for Reagents and Assay Development at AstraZeneca.

For the full story on the launch visit the UC Berkeley News Center.

For more news about the IGI visit their website.